Table 2.

Best response to larotrectinib

Response	Bone sarcoma	GIST	STS	All sarcomas
Evaluable patients	2	4	30	36
Objective response rate, % (95% CI)	50 (1-99)	100 (40-100)	53 (34-72)	58 (41-74)
Best response, n (%)
Complete response	0 (0)	1 (25)	6 (20)	7 (19)
Partial response	1 (50)	3 (75)	10 (33)	14 (39)
Stable disease	1 (50)	0 (0)	11 (37)	12 (33)
Progressive disease	0 (0)	0 (0)	2 (7)	2 (6)
Not determineda	0 (0)	0 (0)	1 (3)	1 (3)

CI, confidence interval; GIST, gastrointestinal stromal tumors; STS, soft tissue sarcoma.

^aPatients that discontinued treatment without evaluable post-baseline assessments.